Utibapril manufacturers
- Utibapril
-
- $2500.00
-
2026-07-27
- CAS:109683-61-6
- Purity:
- Supply Ability: 10g
- Utibapril
-
- $2500.00
-
2026-07-27
- CAS:109683-61-6
- Purity:
- Supply Ability: 10g
- Utibapril
-
- $2500.00
-
2025-07-18
- CAS:109683-61-6
- Purity:
- Supply Ability: 10g
|
| | Utibapril Basic information |
| Product Name: | Utibapril | | Synonyms: | (2S)-5-tert-Butyl-3-[(2S)-2-[[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino]propanoyl]-2,3-dihydro-1,3,4-thiadiazole-2β-carboxylic acid;FPL-63547;Utibapril;1,3,4-Thiadiazole-2-carboxylic acid, 5-(1,1-dimethylethyl)-3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-2,3-dihydro-, (2S)- | | CAS: | 109683-61-6 | | MF: | C22H31N3O5S | | MW: | 449.57 | | EINECS: | | | Product Categories: | | | Mol File: | 109683-61-6.mol |  |
| | Utibapril Chemical Properties |
| Melting point | 165-168 °C | | Boiling point | 597.547±60.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.246±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 0.295±0.40(predicted) |
| | Utibapril Usage And Synthesis |
| Uses | Utibapril is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activities. | | in vivo | Utibapril significantly inhibits plasma, renal, and vascular ACE but not ventricular ACE activity. Utibapril (2 μg/kg/day) significantly inhibits vascular ACE activity, and Utibapril (250 μg/kg/day) results in a significant inhibition of plasma ACE. Furthermore, angiotensin I-induced decreases in coronary flow in the isolated heart are significantly inhibited after treatment with the higher doses of utibapril[1]. FPL 63547 is rapidly and extensively excreted as the diacid in the bile but appeared in the urine in negligible amounts[2]. | | References | [1] Buikema H, et al. Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. J Cardiovasc Pharmacol. 1997 May;29(5):684-91. DOI:10.1097/00005344-199705000-00018
[2] Carr RD, et al. Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin-converting enzyme, in the rat. Br J Pharmacol. 1990 May;100(1):90-4. DOI:10.1111/j.1476-5381.1990.tb12057.x |
| | Utibapril Preparation Products And Raw materials |
|